Premium
Central effects and effective dose determination of suriclone (double‐blind, controlled, phase I safety and quantitative pharmaco‐EEG study)
Author(s) -
Itil Turan M.,
Me Gopi N.,
Dreyfus JeanFrancois,
Bozak M. Mahir,
Songar Ayhan,
Lucadamo Frank
Publication year - 1984
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430040204
Subject(s) - anxiolytic , diazepam , pharmacology , effective dose (radiation) , electroencephalography , drug , medicine , anesthesia , receptor , psychiatry , radiology
Suriclone, a nonbenzodiazepine drug, shown to be anxiolytic in animal pharmacology, was investigated within a single dose tolerance and efficacy study using quantitative pharmaco‐EEG. The investigation showed that suriclone is tolerable in single oral doses of up to 0.8 mg, the highest dose given in healthy volunteers. The minimum effective dose producing statistically significant CNS action was 0.3 mg. Suriclone produced significant dose‐ and time‐related CNS effects. The onset of these effects was later than that of diazepam and its duration of action was longer. Suriclone was classified by the HZI computer EEG drug data base as anxiolytic at high doses. Among a variety of anxiolytics, the CNS effect of suriclone was most similar to that of diazepam. The optimal anxiolytic effective single dose of suriclone was predicted to be 0.6 mg.